Category: Markets
Published: 2026-07-16T11:29:57.000Z
Abbott announced its second-quarter 2026 financial results, reporting a 13.0% increase in sales and a 4.8% comparable sales growth. The company also raised its full-year 2026 adjusted diluted EPS guidance to $5.45 to $5.60, up from the previous range of $5.38 to $5.58. Key business highlights include progress in coronary intravascular lithotripsy, new data for pulsed field ablation and conduction system pacing, CE Mark for Libre® Duo, and FDA submission for the Amulet™ 360 LAA device.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.